Levy J H
Department of Anesthesiology, Emory University School of Medicine, and Division of Cardiothoracic Anesthesiology, Emory Healthcare, Atlanta, Georgia 30322, USA.
Ann Thorac Surg. 2000 Aug;70(2 Suppl):S9-11. doi: 10.1016/s0003-4975(00)01603-9.
A variety of measures may affect bleeding and transfusion requirements in abciximab-treated patients. These measures include recognition of the risk factors for increased bleeding and transfusion requirements, use of proper transfusion practices, conservation or increasing of red cell mass, appropriate heparin dosing and protamine reversal, reversal of anticoagulation, awareness of factors that affect activated clotting time (ACT), and appropriate anticoagulation for cardiopulmonary bypass.
多种措施可能会影响使用阿昔单抗治疗的患者的出血情况及输血需求。这些措施包括识别出血及输血需求增加的风险因素、采用恰当的输血操作、保存或增加红细胞量、适当的肝素给药及鱼精蛋白中和、抗凝逆转、了解影响活化凝血时间（ACT）的因素以及体外循环时的适当抗凝。
